Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 12

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 12
---
 important element of our
strategy for developing, manufacturing and commercializing our drug candidates is entering into partnerships and strategic alliances with
other pharmaceutical companies or other industry participants.

Any partnerships or alliances
we have or may have in the future may be terminated for reasons beyond our control or we may not be able to negotiate future alliances
on acceptable terms, if at all. These arrangements may result in us receiving less revenue than if we sold our products directly, may
place the development, sales and marketing of our products outside of our control, may require us to relinquish important rights or may
otherwise be on unfavorable terms. Collaborative arrangements or strategic alliances will also subject us to a number of risks, including
the risk that:

  we may not be able to control the amount and timing of resources that our strategic partner/collaborators may devote to the drug candidates;  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  strategic partner/collaborators may experience financial difficulties;  
 ──────────────────────────────────────────────────────────────────────────

  the failure to successfully collaborate with third parties may delay, prevent or otherwise impair the development or commercialization of our drug candidates or revenue expectations;  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  products being developed by partners/collaborators may never reach commercial stage resulting in reduced or even no milestone or royalty payments;  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  business combinations or significant changes in a collaborator’s business strategy may also adversely affect a collaborator’s willingness or ability to complete their obligations under any arra...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  a collaborator could independently move forward with a competing product developed either independently or in collaboration with others, including our competitors; and  

  collaborative arrangements are often terminated or allowed to expire, which would delay the development and may increase the cost of developing drug candidates.  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Because we rely on third party manufacturing and supply partners,
our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be
of satisfactory quantity